Drugs / umbilical cord blood NK cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06631391 | Nov 2024 → Nov 2026 expected | neuroblastoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06848582 | Nov 2024 → Feb 2026 overdue | soft tissue sarcoma | Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | umbilical cord blood NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06848582 ↗ |
| Modality | Cell therapy | “umbilical cord blood NK cell therapy” NCT06631391 ↗ |